/
BCYC
$4.15+$0.05 (+1.22%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$286.2M
70M shares
52-week range
$3.92 – $9.18
4% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
ADRC
Borrow rate
0.27%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-26.21
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $7.1M | $13.8M | $10.4M | $11.7M | $14.5M | $27.0M | $35.3M | $72.6M |
| Cost of revenue | $20.8M | $25.5M | $33.1M | $0 | $0 | $156.5M | $173.0M | $0 |
| Gross profit | −$13.6M | −$11.7M | −$22.8M | $11.7M | $14.5M | −$129.5M | −$137.7M | $72.6M |
| Gross margin | -190.9% | -85.1% | -219.0% | 100.0% | 100.0% | -480.1% | -390.3% | 100.0% |
| R&D | $20.8M | $31.6M | $33.1M | $44.9M | $81.6M | $156.5M | $173.0M | $240.3M |
| Operating income | −$21.7M | −$26.3M | −$52.0M | −$65.6M | −$116.7M | −$189.9M | −$209.9M | −$247.7M |
| EBITDA | −$21.5M | −$25.3M | −$50.7M | −$64.1M | −$107.2M | −$169.4M | −$164.9M | −$212.2M |
| Net income | −$21.8M | −$30.6M | −$51.0M | −$66.8M | −$112.7M | −$180.7M | −$169.0M | −$219.0M |
| Net margin | -306.1% | -221.8% | -491.0% | -571.2% | -779.3% | -669.7% | -479.2% | -301.7% |
| EPS (diluted) | -1.64 | -2.77 | -2.66 | -2.67 | -3.80 | -5.08 | -2.90 | -3.16 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $23M | $-2.26 | $-2.69–$-1.49 | 8 |
| 2027 | $16M | $-2.33 | $-2.87–$-1.55 | 7 |
| 2028 | $27M | $-2.17 | $-3.06–$-1.29 | 6 |
| 2029 | $46M | $-1.64 | $-2.62–$-0.78 | 4 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Bicycle Therapeutics plc American Depositary Shares
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.
www.bicycletherapeutics.com- Employees
- 288
- IPO / List date
- May 23, 2019
- HQ
- CAMBRIDGE, X0
Held by traders on TradeandTell
No one on the platform currently holds BCYC.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 979,300 | $4.5M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded BCYC yet.
